valproic acid

(redirected from Depakene)
Also found in: Thesaurus, Medical.

val·pro·ic acid

 (văl-prō′ĭk)
n.
An anticonvulsive drug, C8H15NaO2, given orally and by injection to treat epilepsy.

valproic acid

(vælˈprəʊɪk)
n
1. (Pharmacology) a synthetic crystalline compound, used as an anticonvulsive to treat seizure disorders. Formula C7H15COOH
2. (Chemistry) a synthetic crystalline compound, used as an anticonvulsive to treat seizure disorders. Formula C7H15COOH
[C20: from val(erian) + pro(pyl) + -ic]
valˈproate n
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.valproic acid - anticonvulsant (trade name Depokene) used to prevent some kinds of seizures
anticonvulsant, anticonvulsant drug, antiepileptic, antiepileptic drug - a drug used to treat or prevent convulsions (as in epilepsy)
Translations

valproic acid, valproate sodium

(USAN), valproate n ácido valproico, valproato sódico or de sodio, valproato
References in periodicals archive ?
Products include valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and generic versions.
Valproate products include valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and generic versions of these products.
Antiseizure medications (also called anticonvulsants) such as valproic acid (Depakene) and divalproex (Depakote) can have a mood-stabilizing effect in people with bipolar disorder.
Sold under brand names that include Depakene, Depakote and Stavzor, valproic acid is used to smooth out the mood swings of people with manic-depressive disorder and related conditions.
17 June 2011 - Japanese Kyowa Hakko Kirin Co Ltd (TYO: 4151) said yesterday that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved additional indication, dosage and administration of Depakene (sodium valproate) for suppressing the onset of migraine attacks.
Valproic acid, marketed as Depakene and as Stavzor, was approved in 1978 for treating epilepsy.
TABLE 6 Agents with reported potential drug interactions (20-23, 25-26, 32, 33, 45) Drug Possible interactions Histamine 2 Fluoxetine (Prozac), chemotherapy drugs, cyclosporine receptor (Sandimmune, Neoral, Restasis), warfarin (Coumadin, antagonists Jantoven), carbamazepine (Carbatrol, Equetro, Tegretol), phenytoin (Dilantin), isoniazid (Nydrazid), ciprofloxacin (Cipro, Proquin XR), ketoconazole (Nizoral, Xolegel), valproic acid (Depakene, Depakote, Stavzor), theophylline (Theo-Dur, Theolair, Slo-phyllin), and midazolam Proton pump Warfarin (Coumadin Jantoven), atazanavir (Rayataz), inhibitors ketoconazole (Nizoral, Xolegel), iron salts, digoxin (Lanoxin, Digitek), cyclosporine (Sandimmune, Neoral, Restasis), and tacrolimus (Protopic, Prograf), clopidogrel (Plavix)
Depakote and Depakene), a leading antiepileptic drug currently approved for use in the treatment of epilepsy, migraine prophylaxis and bipolar disease, in preclinical studies completed to date, this stereoisomer of valnoctamide has not been associated with the safety concerns (i.e., teratogenicity, and hepatotoxicity) of valproate and its related analogues.
Some of the studies used valproate (Depacon); others used divalproex (Depakote) or valproic acid (Depakene).
The metaanalysis, presented during a poster session, was funded by Abbott Laboratories, which manufactures different types of valproate (Depakote, Depakene, and Depacon).
Among the company's drugs for the central nervous system are carbamazepine suspension, the generic equivalent of Novartis Pharmaceuticals Corp.'s Tegretol; fluoxetine HCI oral suspension, a generic version of Eli Lilly and Co.'s Prozac liquid oral suspension; and valproic acid syrup, a generic version of Abbott Laboratories' Depakene syrup.